This page lists the SEC filings reported by SILVERARC CAPITAL MANAGEMENT, LLC.
Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
---|---|---|---|---|---|---|
SC 13G | 2024-02-14 | SILVERARC CAPITAL MANAGEMENT, LLC | Evogene Ltd. | 3,100,000 | 6.1% | EDGAR |
SC 13G | 2024-02-14 | SILVERARC CAPITAL MANAGEMENT, LLC | Molecular Templates, Inc. | 354,608 | 6.6% | EDGAR |
SC 13G | 2024-02-14 | SILVERARC CAPITAL MANAGEMENT, LLC | Mersana Therapeutics, Inc. | 6,420,136 | 5.3% | EDGAR |
SC 13G/A | 2023-02-08 | SILVERARC CAPITAL MANAGEMENT, LLC | Benitec Biopharma Inc. | 0 | 0.0% | EDGAR |
SC 13G | 2022-02-09 | SILVERARC CAPITAL MANAGEMENT, LLC | Benitec Biopharma Inc. | 587,499 | 7.2% | EDGAR |
SC 13G | 2022-02-09 | SILVERARC CAPITAL MANAGEMENT, LLC | Benitec Biopharma Inc. | 587,499 | 7.2% | EDGAR |
SC 13G | 2022-02-09 | SILVERARC CAPITAL MANAGEMENT, LLC | Benitec Biopharma Inc. | 587,499 | 7.2% | EDGAR |
SC 13G/A | 2022-02-08 | SILVERARC CAPITAL MANAGEMENT, LLC | DELCATH SYSTEMS, INC. | 0 | 0.0% | EDGAR |
SC 13G | 2021-03-10 | SILVERARC CAPITAL MANAGEMENT, LLC | DELCATH SYSTEMS, INC. | 351,616 | 5.9% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.